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Babak Shahbaba 1, Robert Tibshirani 2, Catherine Shachaf 3, and Sylvia K. Plevritis 4
Abstract. Gene expression microarray technologies provide the simultaneous measurements of a
large number of genes. Typical analyses of such data focus on the individual genes, but recent
work has demonstrated that evaluating changes in expression across predefined sets of genes often
increases statistical power and produces more robust results. We introduce a new methodology
for identifying gene sets that are differentially expressed under varying experimental conditions.
Our approach uses a hierarchical Bayesian framework where a hyperparameter measures the sig-
nificance of each gene set. Using simulated data, we compare our proposed method to alternative
approaches, such as Gene Set Enrichment Analysis (GSEA) and Gene Set Analysis (GSA). Our
approach provides the best overall performance. We also discuss the application of our method to
experimental data based on p53 mutation status.
1 Introduction
High throughput biological experiments such as gene expression microarray analysis have tradition-
ally focused on identifying individual genes that are differentially expressed across experimental
conditions (see for example, Baldi and Long, 2001; Efron et al., 2001; Newton et al., 2001; Tusher
et al., 2001; Gottardo, 2003; Ishwaran and Rao, 2003, 2005; Smyth, 2004; Delmar et al., 2005;
Do et al., 2005; Opgen-Rhein and Strimmer, 2007). These studies typically involve simultaneous
analysis of tens of thousands of candidate genes with relatively small number of samples, often
much less than 100. While statistical methods developed for analyzing such data are easy to im-
plement, interpretation of the resulting list of significant genes is far from trivial. As stated by
Subramanian et al. (2005), it is not uncommon for such studies to either produce a large list of
significant candidates with no unifying biological theme or identify no significant gene at all (e.g.,
after correcting for multiple hypothesis testing in a frequentist framework). Moreover, on many
occasions, there is little overlap between findings of different research groups for the same biological
system (Subramanian et al., 2005); that is, the results have low reproducibility. These issues are
partly due to the oversimplification of the problem (e.g., ignoring the interconnectivity of genes) in
order to make statistical analysis of data feasible.
In recent years, several methods have been proposed to overcome these limitations by incorpo-
rating biological knowledge in the data analysis. These methods produce inferences on predefined
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sets of genes as opposed to individual genes (Virtaneva et al., 2001; Pavlidis et al., 2002; Mootha
et al., 2003; Smyth, 2004; Rahnenfuhrer et al., 2004; Subramanian et al., 2005; Barry et al., 2005;
Newton et al., 2007; Efron and Tibshirani, 2007). The gene sets are defined based on prior biologi-
cal information such as biochemical pathways or similarity of gene sequences. Shifting the focus of
analysis from individual genes towards groups of genes often increases statistical power and leads
to more reproducible results (Efron and Tibshirani, 2007).
Typically, gene set analysis methods start with a collection of gene sets S1, S2, . . . , SK defined
based on some prior information. Then, for each individual gene, a statistic, z, (e.g., two sample
t-statistic), is calculated to measure the amount of support for its corresponding hypothesis. Then,
for each gene set Ss, a set-level statistic Ts is calculated as a function of individual statistics
zs = {zs1, zs2, ..., zs`s}, where `s is the number of genes assigned to that set. The significance of Ts
is assessed by using a permutation test where the class labels are repeatedly permuted.
One of the most widely used methods for analyzing gene sets is Gene Set Enrichment Analysis
(GSEA). The gene-level test statistic, z, in GSEA is calculated using t-test when the analysis
involves two classes (e.g., treatment vs. control). The set-level statistic for each set is defined
as a signed Kolmogorov-Smirnov (KS) statistic based on the distribution of zs and that of its
complement, zcs , which includes all genes that are not included in the set s. Recall that the KS
statistic quantifies the distance between the empirical cumulative distribution function of a sample
(in this case, the gene set of interest) and that of a reference sample (in this case, the complement
set). The sign represents the direction of shift in the distribution.
The GSEA method poses several statistical concerns (Damian and Gorfine, 2004; Efron and
Tibshirani, 2007). For example, Efron and Tibshirani (2007) argue that while GSEAs dependence
on KS is reasonable, it is not necessarily the best choice. This is because KS is sensitive to change
in the distribution of z scores across the whole distribution, whereas we are interested mainly in
changes in lower and upper distribution tails, where genes are statistically significant. Efron and
Tibshirani (2007) propose an alternative approach that has a significant power advantage over
GSEA. Their method uses the a new statistic called maxmean. For each gene set, maxmean is
calculated by first separating negative and positive z-scores (i.e., separating downregulated and
upregulated genes within the set). Then, we set the positive z-scores to 0 and take the average over
all scores (zeros included). We denote this average as T−. Next, we set all negative z-scores to 0
and take the average over all scores (zeros include). We denote this average as T+. The maxmean
statistic, Tmax, is the larger average in absolute value; that is, Tmax = max(|T−1|, |T+|).
In their paper, Efron and Tibshirani (2007) also argue that any method for assessing gene sets
should compare a given gene set score not only to scores from permutations of the sample labels,
but also to scores from sets formed by random selections of genes. To illustrate this concept, they
generated data on 1000 genes and 50 samples, with each consecutive non-overlapping block of 20
genes considered to be a gene set. The first 25 samples are the control group, and the second
25 samples are the treatment group. First they generated each data value independently from
N(0, 1), and then they increased the expression values for the treatment group by the constant
2.5 for the first 10 genes in each gene set. This way, all of the maxmean scores look significantly
large compared to the permutation values. But they argue that given the way that the data were
generated, there seems to be nothing special about any one gene set. To address this issue, they
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propose restandardization, where they center and scale the maxmean statistic by its mean and
standard deviation under the randomization of genes among gene sets. This way, no gene set would
be selected as significant.
Although the maxmean statistic has several advantages (e.g., higher statistical power) over other
statistics, it has some limitations. More specifically, we believe that the maxmean statistic performs
well when almost all significant candidate genes in a set are either upregulated or downregulated.
To illustrate this, consider two gene sets, S1 and S2, each with 100 genes. In the first set, 50 genes
have z-scores equal to −2, and the z-scores of the remaining genes are zero. The second gene set
also has 50 z-scores of −2; however, the remaining genes have z-scores equal to 1.5. While it is
possible that for a given experiment one might regard S2 as a more significant gene set compared
to S1, the maxmean score for both gene sets is 1. In general, maxmean mainly captures changes in
the dominating regulation direction, ignoring (to some extent) when differentially expressed genes
within a set do not necessarily move in the same direction.
In this paper, we propose an alternative hierarchical Bayesian method for gene set analysis. In
the next section, we describe our method in detail. In Section 3, we use simulated data to evaluate
the performance of our model. We compare our model to several other approaches including GSEA
(Subramanian et al., 2005) and GSA (Efron and Tibshirani, 2007). Section 4 shows the results from
applying our model to real data. Finally, Section 5 is devoted to discussion and future directions.
2 Bayesian analysis of gene sets
We denote the ith observed expression of gene g in set s as ysgi. Given the class label xi, where
xi ∈ {0, 1} (i.e., control=0, treatment=1), we assume the following model for ysgi:
ysgi = αsg + βsgxi + sgi g = 1, 2, . . . , `s
sgi ∼ N(0, σ2sg)
Here, αsg is the overall mean of expression for gene Gg in the set Ss, and βsg is the expected change
in the expression of this gene between the control group (i.e., xi = 0) and the treatment group (i.e.,
xi = 1). The model therefore can be considered as a simple linear mixed-effects model, where βsg
are the random effects associated with the class variable. We could therefore use a mixed effects
ANOVA model to evaluate the overall significance of a gene set, where the null hypothesis is defined
as H0 : βs1 = . . . = βs`s = 0. Alternatively, assuming that βsg ∼ N(0, τ2s ), we have H0 : τ2s = 0.
Standard computer packages such as nlme and lme4 in R could be used for such analysis. Note
however that the clustering of observations is based on genes (i.e., variables) as opposed to subjects
(which is more common in mixed-effects models).
2.1 A hierarchical Bayesian model
A simple mixed-effects model with a fixed intercept and a random effect parameter is equivalent to
a simple hierarchical Bayesian model with uniform prior on the intercept and a normal prior (with
mean 0 and unknown variance) on the random effect parameter. However, compared to mixed-
effects models, hierarchical Bayesian models are more flexible, and as discussed in this paper,
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they can easily handle more complex data structure such as overlaps between gene sets. Using
appropriately informative (i.e., reasonably broad) hyperpriors, these models can also accommodate
shrinkage of β’s and their corresponding variance τ2s towards zero when the gene set as a whole is
not significant. This way, they avoid strong influences of one or two differentially expressed genes
on the overall measure of significance for the set. Moreover, by using more flexible priors, such as
the mixture prior proposed in the in this paper, we can mitigate the negative effect of wrong model
assumptions (e.g., normality of random effects when they are not normally distributed). Therefore,
we believe that models with random effects are more naturally discussed within the hierarchical
Bayesian framework where by default all parameters are considered to be random (in general, there
is no fixed effect). Here, we use the following prior distributions for the parameters of our model:
σ2sg|ξ, η ∼ Inv-χ2(ξ, η2)
αsg|γ ∼ N(0, γ2)
βsg|τ ∼ N(0, τ2s )
Note that the priors for σ2sg and αsg are the same for all genes regardless of their associated gene
sets. We could set ξ, η and γ to some constant values such that the resulting distributions are
appropriately broad giving reasonable prior probability to the set of possible values. For simplicity,
however, we use non-informative priors for this parameters. To this end, we assume P (αsg, σ
2
sg) ∝
1/σ2sg. For σ
2
sg, this is equivalent to setting ξ = 0 and η = 1. For αsg, this is equivalent to the limit
of the normal distribution when we take γ2 →∞.
For the prior of βsg, we regard τ
2
s as hyperparameter with its own hyperprior, τ
2
s ∼ Inv-χ2(ν, φ2).
Note that τ2s is a shared by all genes in the set Ss (throughout this paper, we assume that gene
expression values are normalized). The role of τ2s is to adjust the distribution of β’s within a
gene set. If a gene is not differentially expressed, its corresponding β moves close to zero in
posterior. This will be accommodated by small values of τ2s . If a large number of genes in a set
are not differentially expressed (i.e., negligible amounts of shift are observed), the hyperparameter
τ2s , which is shared by all the genes in the set, would shrink towards zero. If a gene is in fact
significant, we expect a large shift in its expression value for the case group, which in turn makes
the posterior distribution of β move away from zero. When the gene set includes a large number
of significant genes, τ2s becomes larger in posterior to allow for large values of β. Therefore, we can
evaluate the overall significance of a gene set based on the posterior distribution of τ2s : for a less
significant gene set, the posterior distribution of τ2 shrinks towards zero, whereas for a significant
gene set, the posterior distribution would higher probabilities to large values of τ2. Similarly, we
can evaluate significance of individual genes within a set using the posterior distribution of their
corresponding β: the posterior distribution of β for a more significant gene would be away from
zero (we can quantify significance of gene by measuring the posterior tail probability of zero).
This hierarchical Bayesian model introduces prior correlation between the absolute values of
β’s for genes within one set, while β’s associated with genes in different sets remain independent.
We illustrate this by showing samples simulated from the above hierarchical prior. Consider two
gene sets each with two genes whose expressions are measured under two different experimental
conditions. We generate samples from the prior as follows. For each gene set, we first sample
η ∼ Inv−χ2(1, 0.5). Next, given the current value of η, we sample τ1 and τ2 from Inv−χ2(1, eta).
Finally, we sample 100 β’s from N(0, τ) and measure the correlation between the absolute values
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Figure 1: Comparing the histogram of correlation between absolute values of β’s for two genes in
one set (solid line) to the corresponding histogram of the correlation between the absolute values
of β’s for genes in two different sets (dashed line).
of β’s for genes in one set (denoted as r1) as well as the correlation between the absolute values of
β’s for genes in two different gene sets (denoted as r0). We repeat this procedure 1000 times. The
histograms for r0 and r1 are presented in Figure 1. As shown, the correlation between |β|’s tends
to be higher for genes within the same set compared to that of genes in different sets. Therefore, if
the gene sets are defined properly, we expect that the informative prior incorporated in our model
results in better performance in terms of identifying significant pathways.
To illustrate the above approach, we use a simple simulation study. We first generate a dataset
with 1000 candidate genes and 30 samples such that the first 15 samples are assigned to the control
group, and the rest to treatment group. We assume that each consecutive non-overlapping block
of 20 genes forms a set; that is, there are 50 gene sets in total. The values for all genes are first
sampled independently from N(0, 1). To make a gene significant, we add then the constant 1 to
the expression values for the treatment group. In Set 1 we make all 20 genes significant. In Set 2,
we make only half of the genes (i.e., 10) significant. We reduce the number of significant genes to 5
for Set 3 and to 2 for Set 4. We keep the remaining 46 gene sets (i.e., Sets 5-50) as non significant.
Therefor, the significance of gene sets reduces from Set 1 to Set 4, and there is no association
between the class variable and Sets 5-50. We use our hierarchical Bayesian method to evaluate the
significance of these gene sets.
Figure 2 shows the posterior distribution of τ2 for the 50 gene sets. As we can see, there is a
clear separation between the posterior distribution of τ2 for Set 1 and the posterior distributions
of τ2 for Sets 5-50. As the number of significant genes reduces from Set 1 to Set 4, the posterior
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Figure 2: Left panel: Posterior distribution of the hyperparameter τ2 for 50 simulated gene sets.
Sets 1-4 have 20, 10, 5, and 2 significant genes respectively. Sets 5-50 contain no significant
genes. Right panel: Posterior distribution of β for individual genes in Set 2, where only 10 genes
are significantly upregulated (the constant 1 is added to the expression values for the treatment
group).
distribution of τ2 shrinks towards 0. The posterior distribution of τ2 for Set 4 (where only 2 genes
out of 20 are significant) is very similar to the posterior distribution of τ2 for Sets 5-50. The
posterior expectation of τ2 for Sets 1 to 4 are 1.11, 0.55, 0.23, and 0.02 respectively. The posterior
expectation of τ2 for Sets 5-50 ranges from 0.02 to 0.05.
As mentioned above, we can use the posterior distribution of β’s to evaluate the significance
of individual genes. Figure ?? shows the posterior distribution of β for individual genes in Set 2
(where only 10 genes out of 20 are significant). As we can see, for the significant genes, the posterior
distributions of β moves away from 0 (in this case to the right since genes are upregulated).
2.2 Gene set selection via mixture priors
The above approach could be useful for ranking gene sets in terms of their significance based on,
for example, posterior expectations of τ2; that is, the higher the posterior expectation of τ2, the
more significant the gene set. However, in many practical problems, an automatic mechanism
for selecting significant gene sets (or genes) is required. For linear mixed-effects models, we could
obviously use p-values with a cutoff that has been adjusted to control the family-wise error rate (i.e.,
the chance of making at least one type I error) or false discovery rate (i.e., the expected proportion
of false positives among the rejected null hypotheses). For our model, we do this by using a mixture
prior, similar to that of George and Mcculloch (1993) and Ishwaran and Rao (2005), instead of a
simple scaled-inv-χ2 distribution as the prior of τ2s . That is, we assume
τ2s ∼ (1− λ)F0 + λF1,
6
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
τ2
D
en
si
ty
Inv-χ2(5, 0.50)
Inv-χ2(5, 0.25)
Inv-χ2(5, 0.01)
Figure 3: Three scaled-inv-χ2 distributions with the same degrees of freedom and different scale
parameters. As the scale parameter increases, the distribution moves to the right giving higher
probabilities to large values of τ2.
where F0 and F1 are the distributions of τ
2
s under the null and alternative hypotheses respectively,
and λ is the probability that τ2s is generated under the alternative. As mentioned before, under
the null hypothesis of no relationship between a gene set and the class variable, we have τ2s = 0.
Therefore, we could assume that under the null F0 ≡ δ0 (i.e., point mass distribution at 0). However,
making such assumption is appropriate if we are using the correct model (e.g., all the relevant
factors are included in the model), and data in fact conform with the model assumptions. This
rarely happens in reality. A more reasonable assumption is that under the null τ2s are quite small
and close to zero. Therefore, we assume the following mixture prior for τ2s :
τ2s |λ, φ0, φ1 ∼ (1− λ) Inv-χ2(ν, φ20) + λ Inv-χ2(ν, φ20 + φ21)
φ20, φ
2
1 ∼ Gamma(1, 1)
ν ∼ Gamma(1, 1)
λ ∼ Beta(1, 1)
This way, the distribution of τ2s are assumed to come from two different distributions: a scaled-
inv-χ2 distribution with a relatively small scale parameter φ20, and a scaled-inv-χ
2 with a relatively
larger scale parameter φ20 + φ
2
1. As shown in Figure 4, for a given degrees of freedom, as the
scale parameter increases, scaled-inv-χ2 distribution gives higher probability to large values of
random variable (i.e., the distribution moves to the right). Therefore, our prior separates τ2s into
two groups. One group includes small values of τ2 with Inv-χ2(ν, φ20) distribution. These τ
2
s are
assumed to be generated under the null hypothesis. The second group includes large values of τ2
with Inv-χ2(ν, φ20 + φ
2
1). These τ
2
s are assumed to be generated under the alternative hypothesis.
For λ, we use a conjugate Beta prior. Throughout this paper, we assume a = b = 1, which
is equivalent to the Uniform(0, 1) distribution, which is a noninformative prior. In practice, we
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Figure 4: Histogram of P (v = 0|D) for simulated data where all gene sets are equally upregulated
such that no gene set is special.
might expect that only a small number of gene sets are significant and use informative priors such
as Beta(1, 10).
To facilitate posterior sampling, we use the data augmentation approach (Tanner and Wong,
1987) by introducing binary latent variables vs ∼ Bernoulli(λ) such that
τ2s |vs, φ0, φ1 ∼ (1− vs) Inv-χ2(ν, φ20) + vs Inv-χ2(ν, φ20 + φ21).
Alternatively, we can write the above prior as{
τ2s |vs = 0, ν, φ0 ∼ Inv-χ2(ν, φ20)
τ2s |vs = 1, ν, φ0, φ1 ∼ Inv-χ2(ν, φ20 + φ21)
Note that we can use the posterior distribution of vs given the observed data, D, to evaluate the
significance of each gene set. To this end, we use P (vs = 0|D) (integrated over all other parameters)
as an estimate for the posterior probability of H0 given the data, P (H0|D).
We applied this model to the simulated data discussed above. For Sets 1-4, the estimated values
for P (vs = 0|D) are 0.002, 0.008, 0.06, and 0.99 respectively. For Sets 5-50 (non significant genes
sets) this probability ranges from 0.96 to 1.
One advantage of our model is that it automatically performs a form of what Efron and Tibshirani
(2007) called restandardization. To show this, we generate data similar to the illustrative example
above, but this time we increase the expression values for the treatment group by 1 unit for half
of the genes in every gene set. This way, we make half of the genes in each set upregulated, but
there is nothing special about any of the gene sets. Figure ?? shows the histogram of P (v = 0|D)
for this data set. Notice that the values of P (v = 0|D) are centered around 0.5. They range from
0.29 to 0.77, which is consistent with the fact that no set is special.
2.3 Posterior sampling
The priors used in this paper are all conditionally conjugate except for the priors used for scale
parameters of scaled-inv-χ2 distributions (e.g., ν, φ20 and φ
2
1). Using conjugate priors make posterior
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sampling easier since posterior distributions are conditionally tractable and we can use the Gibbs
sampler. The posterior distributions for σ2sg and αsg given all other parameters are as follows:
σ2sg|. ∼ Inv-χ2
(
n,
∑n
i=1(ysgi − αsg − βsgxi)2
n
)
,
αsg|. ∼ N
(∑n
i (ysgi − βsgxi)
n
,
σ2sg
n
)
.
Samples from the posterior distribution of βsg obtained given the updated values of the above
parameters as well as the current value of τ2s ,
βsg|. ∼ N
( 1
σ2sg
∑n
i (ysgi − αsg)xi
1
τ2s
+
∑n
i xi
σ2sg
,
[ 1
τ2s
+
∑n
i xi
σ2sg
]−1)
The posterior distribution of τ2s has a closed form given the current values of β’s, vs, ν, φ
2
0 and φ
2
1,
τ2s |vs = 0, ν, φ20, β ∼ Inv-χ2
(
ν + `s,
νφ20+
∑`s
g=1(βsg)
2
ν+`s
)
,
τ2s |vs = 1, ν, φ20, φ21, β ∼ Inv-χ2
(
ν + `s,
ν(φ20+φ
2
1)+
∑`s
g=1(βsg)
2
ν0+`s
)
.
We sample vs from a Bernoulli distribution with the following probability:
P (vs = 1|τ2s , ν, φ20, φ21, λ) =
λf(τ2s |ν, φ20 + φ21)
(1− λ)f(τ2s |ν, φ20) + λf(τ2s |ν, φ20 + φ21)
,
where f(τ2s |ν, φ20) and f(τ2s |ν, φ20 +φ21) are densities for scaled-inv-χ2 distributions. The conditional
posterior distribution of λ also has a closed form,
λ ∼ Beta(a+
K∑
s
vs, b+K −
K∑
s
vs).
Here, K is the total number of gene sets.
Because priors for ν, φ20 and φ
2
1 are not conditionally conjugate, we cannot use the Gibbs sampler
for these parameters. Note that the computational burden is negligible. To sample from the
posterior distribution of ν, φ20 and φ
2
1, we use single-variable slice sampling (Neal, 2003). At each
iteration, we use the ”stepping out” procedure to find the interval around the current point and
the ”shrinkage” procedure for sampling from the interval.
3 Results for simulated datasets
We conduct six simulation studies in order to evaluate the performance of our approach, henceforth
called Bayesian Gene Set Analysis (BGSA), in identifying significant sets. More specifically, we
compare our BGSA model to a linear mixed-effects (LME) model, GSEA (Subramanian et al.,
2005), maxmean statistic (Efron and Tibshirani, 2007), and two other summary statistics based on
the mean of zi and the mean of |zi|, which we refer to as Mean.z and Mean.abs.z respectively. For the
LME model, we use lme4 package in R. We evaluate the significance of each gene set by comparing
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two nested models. The first model is a full model that includes the intercepts αsg and random
coefficients βsg. The second model is a reduced model where x is removed from the full model.
The p-value for each gene set is obtained using the anova function in R. For GSEA, we use the
publicly available R package (http://www.broad.mit.edu/gsea) called R-GSEA. Maxmean, Mean.z
and Mean.abs.z statistics are obtained using the GSA software available from http://www-stat.
stanford.edu/~tibs/GSA/index.html. The computer programs for all the above models along
with the R script to simulate data are available online at http://ics.uci.edu/~babak/Codes.
In all six simulations, there are 1000 genes and 10 subjects (5 subjects are the control group
and 5 subjects are the treatment group). The genes are randomly assigned to 50 gene sets. The
number of genes in each set is itself random. The objective of the first simulation is to evaluate
models based on data that conform with the normality assumptions for gene expression and random
effects. To this end, we generate gene expression values by randomly sampling from N(0, 1). For
the first 5 gene sets, we randomly select a subset of genes to be differentially expressed. For each
gene in this subset, we shift the expression values for the treatment group by a constant, which
is randomly sampled from N(0, 1). Note that the amount of shifts is different between genes, it
could be positive (i.e., upregulated) or negative (i.e., downregulated), and it could be large or small.
This procedure is repeated 100 times, each time a new dataset is generated. The above discussed
methods are used for analyzing these datasets. We expect that each method ranks the first 5 sets
as the most significant gene sets.
We follow the same procedure in Simulation 2, but this time, instead of sampling the expression
values fromN(0, 1), we sample them from Gamma(a, 1), where a itself is sampled separately for each
gene from the Uniform(1, 3) distribution. This way, gene expressions are always positive with non-
normal distributions that is skewed to the right. Moreover, the distributions of gene expression are
different between genes. As before, the first 5 gene sets are designed to be differentially expressed;
that is, we sample a subset of genes in these sets and add a random number from N(0, 1) to the
expression values for the treatment group.
For Simulation 3, we follow the same procedure as Simulation 2, but instead of sampling the
amount change in expression for significant genes from N(0, 1), we sample it from 12N(0, 0.5
2) +
1
2N(0, 1), which is a mixture of two normals. This way, the simulated data will not conform with the
normality assumption for random effects in the mixed-effects model, and the normality assumption
for the prior of β’s in our BGSA model.
The objective of Simulation 4 is to evaluate the robustness of models when non-significant gene
sets randomly include a highly significant gene. To this end, we start with the same procedure as
Simulation 3. Then, we randomly select one third of non-significant gene sets (i.e., Sets 6-50), and
shift the expression values for the treatment group by 2 for one of the genes. A robust model should
not consider these gene sets as significant just because one of the genes is differentially expressed.
Thus far, we assumed that the genes are independent. In reality, a gene could be correlated (or
anti-correlated) with other genes. The objective of Simulation 5 is to examine the performance of
models when the independence assumption among genes is violated. To this end, we follow the steps
of Simulation 2, but this time, we randomly select some pairs of genes and make them correlated.
The sampling is performed with replacement so it is possible that more than two genes become
correlated with each other. The correlation coefficient itself is sampled randomly from Uniform(-1,
10
1).
Finally, Simulation 6 is designed to evaluate the performance of the models when the sets share
common genes. This scenario occurs in real studies quite often. For this simulation, we follow the
same steps as Simulation 5 (where some genes are correlated with each other), but this time, we
repeatedly select some of the genes (the number of genes selected is itself random) and add them
to two or more gene sets. To make sure the first 5 gene sets remain relatively more significant
compared to other gene sets, we select non-significant genes with a higher probability compared to
the significant ones (0.95 vs. 0.05). It is still possible that some of the significant genes appear in
the sets that are not significant overall. This would create a situation similar to that of Simulation
4.
For our BGSA model, we ran 4000 Markov chain Monte Carlo (MCMC) iterations, and obtained
the posterior samples after discarding the first 500 iterations (i.e., pre-convergence iterations). The
convergence of the model was evaluated based on the trace plots of hyperparameters (ν, φ20, φ
2
1 and
τ2s ).
The performance of each model is evaluated using the ROC curve which allows for simultaneous
consideration of power (i.e., sensitivity) and type I error (i.e., 1-specificity) without setting an
arbitrary cut-off for significance level. Each point on the curve represents the number of correctly
identified significant gene sets (vertical axis) compared to the number of times a model identified
a non significant gene set as significant (horizontal axis) for different cut-offs. A more accurate
model will have an ROC curve further away from the diagonal line (random model) with perfect
prediction corresponding to the (0, 1) point. The Area under the ROC curve (AUC) is used as a
summary statistic to compare models. For a perfect model, the AUC is equal to 100%. For each
simulation, we regard Sets 1-5 as true positive and all other sets as true negative.
Table 1 shows the average (over 100 repetitions) of AUC values for alternative methods under
different simulation settings. The corresponding standard errors are presented in parentheses.
For Simulation 1, LME outperforms all other models. This was expected since the data in this
simulation are generated exactly according to the assumptions of LME (i.e., gene expressions are
normal, the random effects are normal, and τ2s = 0 under the null). The BGSA model has the
second best performance. Both LME and BGSA are significantly better than Maxmean, GSEA,
Mean.z and Mean.abs.z (using paired t-tests, all the p-values are less than 0.001). In the rest
of simulations, the BGSA model provides the best performance (the improvements over all other
models are statistically significant with p-values less than 0.01). The violation of model assumptions
(especially when the gene sets share common genes) has a more sever impact on LME compared
to BGSA. Finally, our results shows that Maxmean outperforms GSEA in all six simulations. This
is consistent with the findings of Efron and Tibshirani (2007).
4 Results for experimentally-derived data
We apply our method to an experimentally-derived data set obtained based on interrogating the
mutation status of p53 in cancer cell lines from the NCI-60 collection (Ross et al., 2000). This
collection was created to explore gene expression in 60 cell lines using DNA microarrays prepared
by robotically spotting 9,703 human cDNAs on glass microscope slides. The cDNAs included
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Table 1: Comparing our hierarchical Bayesian models to alternative approaches based on the
average (presented in percentage) of area under the ROC curve (AUC) over 100 data sets for each
simulation. The numbers in parentheses show the corresponding standard error for the average
AUC.
GSEA Mean.z Mean.abs.z Maxmean LME BGSA
Simulation 1 66.1 (0.95) 64.9 (0.94) 74.7 (1.26) 81.4 (1.17) 89.1 (0.94) 86.5 (1.08)
Simulation 2 60.4 (0.77) 65.0 (0.98) 69.6 (1.15) 77.2 (1.04) 77.8 (1.06) 82.5 (1.02)
Simulation 3 61.8 (0.77) 61.1 (0.82) 66.0 (1.01) 68.8 (1.11) 71.0 (1.14) 74.1 (1.19)
Simulation 4 61.2 (0.78) 62.6 (0.89) 60.9 (0.81) 65.0 (1.04) 65.1 (1.02) 67.5 (0.92)
Simulation 5 61.8 (0.89) 63.2 (0.93) 70.1 (1.17) 76.0 (1.19) 78.0 (1.22) 83.1 (1.15)
Simulation 6 62.7 (0.81) 65.6 (0.99) 67.6 (1.02) 76.8 (1.18) 74.9 (1.17) 81.4 (1.21)
approximately 8,000 different genes. Subramanian et al. (2005) used these data to identify targets
of the transcription factor p53, which regulates gene expression in response to various signals of
cellular stress. They found the mutational status of the p53 gene for 50 of the NCI-60 cell lines
using the IARC TP53 database (Olivier et al., 2002). Out of 50 cell lines (n = 50), 17 were classified
as normal and the remaining 33 were classified as carrying mutations in the gene.
Using the curated gene sets available from the Molecular Signatures Database (MSigDB), we
allocate genes into 522 gene sets. We use our BGSA to identify the gene sets that are significantly
associated with p53 mutation status. The MCMC simulation ran for 2000 iterations of which the
first 500 were discarded. Table 2 shows the selected pathways by setting the cutoff for P (vs = 0|D)
at 0.1. While most of these gene sets are also identified as significant by Maxmean and GSEA,
there are notable differences between the results based on these methods. For example, Cell Cycle
Regulator, ATM, and BAD pathways, which appear in Table 2, are not selected as significant by
Efron and Tibshirani (2007) and Subramanian et al. (2005). On the other hand, some pathways
such as RAS and NGF are identified as significant by GSA but not by BGSA.
Both the ataxia telangiectasia gene (ATM) and BAD are strongly involved with p53. ATM
encodes a protein kinase that acts as a tumor suppressor. ATM activation, via IR damage to DNA,
stimulates DNA repair and blocks cell cycle progression. One mechanism through which this occurs
is ATM dependent phosphorylation of p53, which causes growth arrest of the cell at a checkpoint
to allow for DNA damage repair or can cause the cell to undergo apoptosis if the damage cannot
be repaired. BAD, as a member of the BCL2 family, is also involved with the p53 pathway. BAD
physically interacts with cytoplasmic p53 thereby preventing p53 from entering the nucleus. BAD
mRNA and protein are increased in response to the upregulated expression of wild-type p53 but
not the mutant p53 in cell lines.
One main concern about gene set analysis methods is how the size of gene sets influences the
result. For our method, there is no strong relationship (the correlation coefficient is 0.07) between
the number of genes in a gene set and P (vs = 0|D).
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Table 2: List of significant gene sets in p53 dataset based on our BGSA model. The sets are selected
by setting the cutoff for P (v = 0|D) at 0.1.
Gene set Number of genes E(τ2|D) P (v = 0|D)
p53 Pathway 16 0.34 0.004
Radiation Sensitivity 26 0.26 0.004
p53 Hypoxia Pathway 20 0.28 0.011
p53 Up 40 0.28 0.016
Cell Cycle Regulator 23 0.19 0.023
DNA Damage Signaling 90 0.15 0.047
ATM Pathway 19 0.19 0.079
g2 Pathway 23 0.17 0.091
BAD Pathway 21 0.15 0.098
5 Discussion and future directions
We propose a new method for evaluating the significance of gene sets using a hierarchical Bayesian
model. While simulation studies show that our approach outperforms other methods, such as GSEA
and GSA, there are ways to further improve our model.
Compared to all other approaches discussed in this paper, our BGSA model is more computa-
tionally intensive. Using an implementation of R script on a Linux CentOS 5.3 machine with 2191
MHz processor speed, 2000 iterations of posterior sampling for p53 dataset takes approximately 20
minutes to run. This is much slower than, for example, the GSA model, which runs for 25 seconds
on the same dataset (with 100 permutations).
In this paper, we assumed that the samples are independent. Our model could be modified for
grouped observations. To do this, we can simply add another random intercept, ωsgi, that varies
from one observation group to the other; that is we modify our model as follows:
ysgij = αsg + ωsgi + βsgxij + sgij , g = 1, 2, . . . , `s,
where i is now the index for to the ith group of observations, and j is the index for observations
within the group. The posterior sampling and inference remain as before.
Our hierarchical Bayesian model could also be extended for problems with multiple samples
(e.g., experimental conditions). For example, the treatment group might be divided into different
treatment options. For such problems, we can modify the prior for β as follows:
βsgc ∼ N(0, τ2s ), c = 1, . . . , C,
where c is the index for the class group (e.g., experimental conditions), and βsgc is the random
effect parameter associated with class c. Note that the control group with c = 0 is considered as
the baseline, and xi is now a vector of dummy variables. In this setting, all β’s in a set are still
controlled by one hyperparameter, τ2s . Alternatively, we could have an additional hyperparameter
for each gene
βsgc ∼ N(0, τ2s ρ2sg)
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This way, ρsg controls all β’s associated with gene g in set s. This setting makes it easier for the
variance of βsg to shrink towards zero if a gene is not significant (i.e., its corresponding β’s are
small) while other genes in the set seem to be significant. If the set as a whole is not signifiant, the
posterior distribution of τs will shrink towards zero to make all β’s (that are associated with set s)
small simultaneously.
Currently, our method does not take into account possible overlaps between gene sets. In
reality, the gene sets are not mutually exclusive. Our approach could easily be extended to
take into account the overlaps between gene sets. We could, for example, modify our prior
such that gene sets that include common genes share common hyperparameters. Without loss
of generality, consider two gene sets Ss = {G1, G2, . . . , Gq, Gs,q+1, Gs,q+2, . . . , Gs`s} and Sr =
{G1, G2, . . . , Gq, Gr,q+1, Gr,q+2, . . . , Gr`r} that share q genes: {G1, . . . , Gq}. We can use the fol-
lowing priors for β’s to account for the overlap:
β1, . . . , βq|τrs ∼ N(0, τ2rs)
βs,q+1, . . . , βs`s |τrs, τs ∼ N(0, τ2s + τ2rs)
βr,q+1, . . . , βr`r |τrs, τr ∼ N(0, τ2r + τ2rs)
This way, if the common genes are not significant, their corresponding hyperparameter, τ2rs, shrinks
towards zero, and the significance of sets Ss and Sr would depend solely on the non-overlapping
genes. However, if the common genes are in fact significant, τ2rs moves away from zero and con-
tributes to the overall significance of both gene sets.
The method proposed in this paper regards the gene sets as known and fixed, as is done in
GSA and GSEA. Therefore, none of these methods take into account the uncertainty regarding the
grouping of genes. In reality, there are many ways to group genes depending on which biological
aspect we consider. A similar concern is recently discussed by Shen and West (2008). Our hierar-
chical Bayesian model could address this issue by assuming multiple grouping schemes each with
its own separate set of hyperparameters.
While the main motivating application for our proposed model is identifying signaling path-
ways (each pathway is associated with a collection of interconnected genes), our method could be
applied to a wide range of problems, for which a large number of hypotheses are grouped into
subsets of related hypotheses according to some prior information. One such problem is functional
neuroimaging for human brain mapping, to study normal versus pathological brain functions. A
typical experiment in this area involves assessing a large number of pixels (each pixel representing a
small area of brain tissue). It is possible to group pixels such that each subset of pixels represents a
different brain region. Another possible application for our method is analysis of single-nucleotide
polymorphisms (SNPs) in genome-wide association studies, in which the objective is to identify
and characterize genetic variants related to common complex diseases. These studies commonly fo-
cus on haplotypes (a set of statistically associated SNPs that are transmitted together as a block)
on a single chromatid. More recently, there has also been suggestions to focus on pathways in
genome-wide association studies (see for example, Luan and Li, 2008).
14
Acknowledgements
The authors also gratefully acknowledge the Young Clinical Scientist Award from FAMRI and NIH
funding from U54CA11967 and U56CA112973.
References
Baldi, P. and A. Long (2001). A bayesian framework for the analysis of microarray expression
data: regularised t-test and statistical inferences of gene expression changes. Bioinformatics 17,
509–519.
Barry, W., A. Nobel, and F. Wright (2005). Significance analysis of functional categories in gene
expression studies: a structured permutation approach. Bioinformatics 21, 1943–1949.
Damian, D. and M. Gorfine (2004). Statistical concerns about the GSEA procedure. Nature
Genetics 36 (663), doi: 10.1038/ng0704–663a.
Delmar, P., S. Robin, D. Roux, and J. Daudin (2005). Mixture model on the variance for differential
analysis of gene expression data. Journal of the Royal Statistical Society, C 54, 31–50.
Do, K., P. Mu¨ller, and F. Tang (2005). A bayesian mixture model for differential gene expression.
Journal of the Royal Statistical Society: Series C (Applied Statistics) 54 (3), 627–644.
Efron, B. and R. Tibshirani (2007). On testing the significance of sets of genes. Annals of Applied
Statistics 1 (1), 107–129.
Efron, B., R. Tibshirani, J. D. Storey, and V. Tusher (2001). Empirical bayes analysis of a mi-
croarray experiment. Journal of the American Statistical Association 96 (456), 1151–1160.
George, E. I. and R. E. Mcculloch (1993). Variable selection via gibbs sampling. Journal of the
American Statistical Association 88 (423), 881–889.
Gottardo, R. (2003). Statistical analysis of microarray data: a Bayesian approach. Biostatistics 4,
597–620.
Ishwaran, H. and J. S. Rao (2003). Detecting differentially expressed genes in microarrays using
bayesian model selection. J. Amer. Statist. Assoc 98, 438–455.
Ishwaran, H. and J. S. Rao (2005). Spike and slab gene selection for multigroup microarray data.
J. Amer. Statist. Assoc 100, 764–780.
Luan, Y. and H. Li (2008). Group Additive Regression Models for Analysis of Genomic Data.
Biostatistics 9, 100–113.
Mootha, V. K., C. Lindgren, K. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver,
M. Carlsson, E. Ridderstrale, E. Laurila, N. Houstis, M. Daly, N. Patterson, J. Mesirov, T. Golub,
P. Tamayo, P. Spiegelman, E. S. Lander, J. Hirschhorn, D. Altshuler, and L. Groop (2003). PGC-
1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated
in human diabetes. Nature Genetics 4, 267 – 273.
15
Neal, R. M. (2003). Slice sampling. Annals of Statistics 31 (3), 705–767.
Newton, M., C. Kendziorski, C. Richmond, B. FR, and T. KW (2001). On differential variability of
expression ratios: improving statistical inference about gene expression changes from microarray
data. Journal of Computational Biology 8 (1), 37–52.
Newton, M., F. Quintana, J. den Boon, S. Sengupta, and P. Ahlquist (2007). Random-set methods
identify distinct aspects of the enrichment signal in gene-set analysis. The Annals of Applied
Statistics 1, 85–106.
Olivier, M., R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris, and P. Hainaut (2002). The iarc tp53
database: New online mutation analysis and recommendations to users. Human Mutation 19 (6),
607–614.
Opgen-Rhein, R. and K. Strimmer (2007). Accurate Ranking of Differentially Expressed Genes
by a Distribution-Free Shrinkage Approach. Statistical Applications in Genetics and Molecular
Biology 6 (1), Article 9.
Pavlidis, P., D. Lewis, and W. Noble (2002). Exploring gene expression data with class scores. In
Proceedings of the Seventh Annual Pacific Symposium on Biocomputing (PSB 00).
Rahnenfuhrer, J., F. Domingues, J. Maydt, and L. T. (2004). Calculating the statistical significance
of changes in pathway activity from gene expression data. Statistical Applications in Genetics
and Molecular Biology 3, Article 16.
Ross, D. T., U. Scherf, M. Eisen, C. Perou, C. Rees, P. Spellman, V. Iyer, S. Jeffrey, M. Van de
Rijn, M. Waltham, A. Pergamenschikov, J. Lee, D. Lashkari, D. Shalon, T. Myers, J. Weinstein,
D. Botstein, and P. Brown (2000). Systematic variation in gene expression patterns in human
cancer cell lines. Nature Genetics 24 (3), 227–235.
Shen, H. and M. West (2008). Bayesian modeling for biological pathway annotation of genomic
signatures. Technical report, Duke University.
Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential expres-
sion in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3,
Article 3.
Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette,
A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov (2005). Gene
set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression
profiles. Proceedings of the National Academy of Sciences 102 (43), 15545–15550.
Tanner, M. A. and W. H. Wong (1987). The calculation of posterior distributions by data augmen-
tation. Journal of the American Statistical Association 82 (398), 528–540.
Tusher, V., R. Tibshirani, and G. Chu (2001). Significance analysis of microarrays applied to the
ionizing radiation response. PNAS 98, 5116–5121.
16
Virtaneva, K., F. A. Wright, S. M. Tanner, B. Yuan, W. J. Lemon, M. A. Caligiuri, C. D. Bloomfield,
A. de La Chapelle, and R. Krahe (2001). Expression profiling reveals fundamental biological
differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl
Acad Sci U S A 98 (3), 1124–1129.
17
